SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is at the center of investor focus as excitement builds around the Artemis II mission and broader optimism for the expanding lunar economy. While some community members remain wary of volatility and potential share offerings, many are actively trading the stock based on its role in critical upcoming space infrastructure projects.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets, Data Centers, and Treasury and Corporate. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The Treasury and Corporate segment includes the company’s proprietary trading and mining activities, as well as the company’s principal investments and related gains and losses. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

Galaxy Digital is facing intense scrutiny and negative sentiment from retail investors, driven by a perceived lack of communication from leadership regarding the Helios data center project and disappointment over the company's performance compared to sector peers. The community is actively debating the stock's future, with many expressing frustration over the recent delisting from the TSX, stagnant price action, and a lack of clear catalysts to break the current trading range.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on March 20, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is trending as investors bet on a potential short squeeze, citing its low float and high institutional ownership reminiscent of previous high-volatility runners. The community is actively discussing recent patent news and corporate updates while speculating on the impact of potential future government defense contracts.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

The Solana community is actively weighing in on a mix of developer-driven innovation, meme coin activity, and broader macroeconomic factors like stablecoin regulatory developments. While some participants are closely monitoring price consolidation and institutional sentiment, others remain focused on the ecosystem's resilience and long-term utility.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing heightened investor interest and stock volatility driven by ongoing M&A speculation, with the community actively comparing its best-in-class obesity pipeline to major competitors like Eli Lilly and Novo Nordisk. Investors are closely monitoring upcoming clinical catalysts, including maintenance dosing data and the status of oral program advancement, while debating the long-term potential for a significant buyout or high-value partnership.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is seeing intense community scrutiny and volatility following the announcement that its ALTO-101 clinical trial for cognitive impairment associated with schizophrenia failed to meet primary statistical endpoints. Investors are actively debating the company's pivot toward its lead program, ALTO-207, while expressing significant frustration over the lack of data transparency and concerns regarding the firm's cash runway and long-term viability.

Mezo is the onchain Bitcoin banking platform owned by its users. Users can access self-service Bitcoin finance without interacting with loan officers, undergoing credit checks, or observing operational hours. It’s just you, your Bitcoin, and permissionless access to financial services 24/7.  Traditional banks profit from your deposits while charging you for access to your own money. Two-sided lending markets trap you with 8-9% variable rates that can spike unpredictably, especially in decentralized financial systems. Both systems put middlemen between you and your wealth.  Mezo eliminates them all, giving you the power to manage your finances intelligently on your own terms.  Deposit Bitcoin as collateral, mint MUSD (a dollar-pegged stablecoin), and use it however you need. Your Bitcoin stays yours while MUSD provides you with instant liquidity. Fixed rates start as low as 1% and stay fixed for the entire life of the loan.  This is self-service banking with complete autonomy. Unlike any traditional banking experience, there are no minimum payments, set repayment schedules, or penalties for early repayment. Close your position tomorrow or keep it open for years.  It’s your Bitcoin and your decision on what to do with it.

MEZO

Mezo is drawing significant investor interest following its listing on Coinbase as a Bitcoin-native economic layer designed to expand utility through staking and governance. Community members are actively debating the token's long-term potential compared to past Bitcoin-based projects while navigating current trading availability across exchange platforms.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is currently seeing heightened investor interest driven by strong earnings results, improved full-year guidance, and a strategic AI infrastructure partnership with SK Telecom. The community is actively debating the stock's long-term potential as an AI-play, with many focusing on its role in high-performance computing pipelines and debating its valuation relative to broader industry growth.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF is gaining significant traction among retail traders due to its direct exposure to SpaceX ahead of an anticipated public listing. The community is actively debating the ETF's low liquidity and AUM structure, with some participants viewing it as a high-potential momentum play while others express skepticism regarding its underlying holdings.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is seeing strong community interest driven by its status as the leading liquidity hub on the Base network, with investors closely watching for a potential cross-chain merger and ongoing protocol revenue growth. Bullish sentiment remains anchored in its core utility as a 'picks and shovels' play, while traders balance enthusiasm for upcoming ecosystem events against broader market volatility and token dilution concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Crescent Biopharma (NASDAQ:CBIO) Shares Pass Above 200-Day Moving Average - Time to Sell?

Crescent Biopharma (NASDAQ:CBIO) Share Price Passes Above 200 Day Moving Average - Should You Sell...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages

Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and three h...

Crescent Biopharma (NASDAQ:CBIO) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded Crescent Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday...

Crescent Biopharma (NASDAQ:CBIO) Price Target Lowered to $22.00 at HC Wainwright

HC Wainwright decreased their price target on shares of Crescent Biopharma from $25.00 to $22.00 and set a "buy" rating for the company in a research note on Monday...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Given Consensus Recommendation of "Buy" by Brokerages

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine ratings firms that are covering the company, Marketbeat.com...

Crescent Biopharma (NASDAQ:CBIO) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Stock Price Passes Above 200 Day Moving Average - Should You Sell...

Crescent Biopharma (NASDAQ:CBIO) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen downgraded shares of Crescent Biopharma from a "hold" rating to a "sell" rating in a report on Saturday...

Crescent Biopharma (NASDAQ:CBIO) Upgraded by Guggenheim to Strong-Buy Rating

Guggenheim upgraded Crescent Biopharma to a "strong-buy" rating and set a $35.00 price objective for the company in a research note on Wednesday...

Crescent Biopharma (NASDAQ:CBIO) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened

Crescent Biopharma (NASDAQ:CBIO) Share Price Crosses Above 200 Day Moving Average - Here's Why...

Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of "Buy" from Brokerages

Shares of Crescent Biopharma, Inc. (NASDAQ:CBIO - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the company, MarketBeat.com...

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Crescent Biopharma Inc.

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

CBIO
Crescent Biopharma Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest CBIO News

CBIOCrescent Biopharma Inc.